SCHEMBL5079017

SCHEMBL5079017

CN(CC(N)=O)c1ncc(NCCNc2ccc([N+](=O)[O-])c(N)n2)nc1-c1ccc(Cl)cc1Cl

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 8/20 0.56
GSK3A P49840 4/20 0.56
CDK1 P06493 3/20 0.56
CCNB2 O95067 2/20 0.55
CCNB1 P14635 2/20 0.55
CCNB3 Q8WWL7 2/20 0.55
SLC9A5 Q14940 1/20 0.39
RPS6KB1 P23443 1/20 0.33
CDK2 P24941 1/20 0.33
LIMK1 P53667 1/20 0.33
TAOK1 Q7L7X3 1/20 0.33
SLK Q9H2G2 1/20 0.33
CLK4 Q9HAZ1 1/20 0.33
CSNK1G1 Q9HCP0 1/20 0.33
POLB P06746 1/20 0.33
HSD11B1 P28845 1/20 0.33
ALDH1A1 P00352 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
CRHR1 P34998 1/20 0.32
MAPT P10636 4/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4669938 0.84 GSK3B (0.66) GSK3BGSK3ACDK1CCNB2CCNB1
SCHEMBL14175422 0.82 GSK3B (0.64) GSK3BGSK3ACDK1CCNB2CCNB1
SCHEMBL4671986 0.82 GSK3B (0.58) GSK3BGSK3ACDK1CCNB2CCNB1
SCHEMBL4399102 0.81 GSK3B (0.67) GSK3BGSK3ACDK1CCNB2CCNB1
SCHEMBL4672216 0.79 GSK3B (0.55) GSK3BGSK3ACDK1CCNB2CCNB1
SCHEMBL5093471 0.78 GSK3B (0.63) GSK3BGSK3ACDK1CCNB2CCNB1
SCHEMBL5099975 0.77 GSK3B (0.63) GSK3BGSK3ACDK1CCNB2CCNB1
SCHEMBL5091527 0.77 GSK3B (0.57) GSK3BGSK3ACDK1CCNB2CCNB1
SCHEMBL5098978 0.77 GSK3B (0.63) GSK3BGSK3ACDK1CCNB2CCNB1
SCHEMBL4401594 0.76 GSK3B (0.75) GSK3BGSK3ACDK1CCNB2CCNB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7384942-B2 3-(2,4-dichlorophenyl)-5-bromoyrazine-2-ylamine; inhibiting the formation of neurofibrillary tangles; neurodegenerative, brain disorders; treatment of Alzheimer's disease with one or more additional agents donepezil or tacrine; anticarcinogenic, antiischemic, antidiabetic; insulin resistance NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2008-06-10 US disclosed
US-6949547-B2 Pyrazine based inhibitors of glycogen synthase kinase 3 CHIRON CORPORATION (US) 2005-09-27 US disclosed